Hadassah Wolfram Syndrome Type 2 Combination Therapy Study
Also known as: Treatment of Wolfram Syndrome Type 2 With the Chelator Deferiprone and Incretin Based Therapy, Deferiprone and acetylcysteine Wolfram syndrome study, Deferiprone acetylcysteine sitagliptin metformin, Ferriprox Reolin Januet, NCT02882477
Institution-led study
Academic Phase 2 study evaluating a combination strategy for genetically diagnosed Wolfram syndrome type 2: deferiprone chelation plus acetylcysteine antioxidant therapy, with sitagliptin/metformin added for participants with diabetes. The component drugs are trial arms/components, not separate industry-sponsored hearing-loss pipeline programs.
Promoted as a verified registry-backed academic Wolfram syndrome type 2 combination-therapy study while preserving status-unknown and study-level caveats. The component drugs are one Hadassah protocol, not distinct HearScape product programs.